A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Condition:   Non-Hodgkin Lymphoma Interventions:   Drug: Epcoritamab;   Drug: Lenalidomide;   Drug: Ibrutinib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride [HCl];   Drug: Prednisone;   Drug: Polatuzumab Sponsors:   AbbVie;   Genmab Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials